Denis Smith

11.0k total citations · 2 hit papers
116 papers, 4.1k citations indexed

About

Denis Smith is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Denis Smith has authored 116 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 28 papers in Epidemiology. Recurrent topics in Denis Smith's work include Colorectal Cancer Treatments and Studies (58 papers), Gastric Cancer Management and Outcomes (28 papers) and Neuroendocrine Tumor Research Advances (26 papers). Denis Smith is often cited by papers focused on Colorectal Cancer Treatments and Studies (58 papers), Gastric Cancer Management and Outcomes (28 papers) and Neuroendocrine Tumor Research Advances (26 papers). Denis Smith collaborates with scholars based in France, United Kingdom and United States. Denis Smith's co-authors include Catherine Lombard‐Bohas, Eric Van Cutsem, Philippe Ruszniewski, Laëtitia Dahan, Juan W. Valle, Jean‐Luc Raoul, Ivan Borbath, Shem Patyna, Éric Raymond and Richard C. Chao and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Denis Smith

109 papers receiving 4.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

2011 1.8k citations Éric Raymond, Laëtitia Dahan et al. profile →
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

2022 501 citations Luis A. Díaz, Kai‐Keen Shiu et al. The Lancet Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Denis Smith	3.3k	2.0k	1.4k	622	584	116	4.1k
Keith Stuart	2.4k 0.7×	2.1k 1.1×	1.3k 0.9×	840 1.4×	491 0.8×	70	4.6k
Richard C. Chao	2.9k 0.9×	1.7k 0.8×	1.2k 0.9×	1.4k 2.2×	304 0.5×	90	4.1k
Jorge Barriuso	2.4k 0.7×	859 0.4×	574 0.4×	908 1.5×	484 0.8×	137	4.0k
Ivan Borbath	4.7k 1.4×	3.3k 1.7×	2.0k 1.4×	1.4k 2.3×	277 0.5×	155	6.3k
James Posey	1.8k 0.5×	957 0.5×	620 0.4×	412 0.7×	225 0.4×	66	2.7k
Gabriele Luppi	3.4k 1.0×	794 0.4×	391 0.3×	1.3k 2.1×	513 0.9×	105	4.3k
Jaume Capdevila	6.6k 2.0×	6.6k 3.4×	4.6k 3.2×	483 0.8×	180 0.3×	128	8.0k
Lawrence S. Blaszkowsky	3.5k 1.1×	1.2k 0.6×	346 0.2×	1.8k 2.9×	657 1.1×	182	5.5k
Heinz‐Josef Klümpen	1.6k 0.5×	903 0.5×	240 0.2×	983 1.6×	369 0.6×	154	3.3k
Hagen F. Kennecke	3.6k 1.1×	566 0.3×	328 0.2×	1.4k 2.3×	786 1.3×	156	5.5k

Countries citing papers authored by Denis Smith

Since Specialization

Citations

This map shows the geographic impact of Denis Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denis Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denis Smith more than expected).

Fields of papers citing papers by Denis Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denis Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denis Smith. The network helps show where Denis Smith may publish in the future.

Co-authorship network of co-authors of Denis Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Denis Smith. A scholar is included among the top collaborators of Denis Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denis Smith. Denis Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lefèvre, Jérémie H., Olivier Dubreuil, Raphaël Colle, et al.. (2025). Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 – PRODIGE 84 phase II trial (PREMICES). Digestive and Liver Disease. 58(1). 51–55.

Fontaine, A., Denis Smith, Jacques Mauillon, et al.. (2025). New RPS20 gene variant in colorectal cancer diagnosis: insight from a large series of patients. Familial Cancer. 24(1). 22–22. 1 indexed citations

Bachet, Jean‐Baptiste, Déwi Vernerey, Christophe Boisson, et al.. (2024). 532P G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study. Annals of Oncology. 35. S447–S447. 1 indexed citations

André, Thierry, Tae Won Kim, Benny Vittrup Jensen, et al.. (2024). Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study. Annals of Oncology. 36(3). 277–284. 27 indexed citations

Borg, Christophe, V. Vendrely, Thierry André, et al.. (2023). 651P DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study. Annals of Oncology. 34. S456–S457. 1 indexed citations

André, Thierry, Tae Won Kim, Benny Vittrup Jensen, et al.. (2023). LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study. Annals of Oncology. 34. S1271–S1272. 12 indexed citations

Lepage, Côme, Astrid Lièvre, Laëtitia Dahan, et al.. (2022). Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study. European Journal of Cancer. 175. 31–40. 13 indexed citations

Pernot, Simon, Olivier Pellerin, Laurent Mineur, et al.. (2022). Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. Digestive and Liver Disease. 54(3). 324–330. 6 indexed citations

Díaz, Luis A., Kai‐Keen Shiu, Tae‐Won Kim, et al.. (2022). Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. The Lancet Oncology. 23(5). 659–670. 501 indexed citations breakdown →

10.

Walter, Thomas, Astrid Lièvre, David Malka, et al.. (2022). LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study. Annals of Oncology. 33. S1412–S1412. 5 indexed citations

11.

Yoshino, Takayuki, Thierry André, Kai‐Keen Shiu, et al.. (2022). O7-3 Pembrolizumab vs chemotherapy in MSI-H / dMMR metastatic colorectal cancer: KEYNOTE-177 final analysis Asia subgroup. Annals of Oncology. 33. S471–S471. 1 indexed citations

12.

André, Thierry, Kai‐Keen Shiu, Benny Vittrup Jensen, et al.. (2021). O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer. Annals of Oncology. 32. S220–S221. 1 indexed citations

13.

Pernot, Simon, Olivier Pellerin, Pascal Artru, et al.. (2020). Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. British Journal of Cancer. 123(4). 518–524. 19 indexed citations

14.

Delemer, Brigitte, Romain Coriat, Denis Smith, et al.. (2020). Evaluation of Nurses’ and Patients’ Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR®): A French Observational Study. Advances in Therapy. 37(9). 3901–3915. 1 indexed citations

15.

André, Thierry, Mayur M. Amonkar, Josephine M. Norquist, et al.. (2020). 396O Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study. Annals of Oncology. 31. S409–S409. 6 indexed citations

16.

Kim, Stéfano, Éric François, Emmanuelle Samalin, et al.. (2017). Docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study). Annals of Oncology. 28. v181–v181. 1 indexed citations

17.

Assénat, Eric, D. Azria, Caroline Mollévi, et al.. (2015). Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial. Oncotarget. 6(14). 12796–12808. 54 indexed citations

18.

Lévi, Françis, Valérie Boige, Mohamed Hebbar, et al.. (2013). Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228).. Journal of Clinical Oncology. 31(4_suppl). 466–466. 1 indexed citations

19.

Vinik, Aaron I., Eric Van Cutsem, Patricia Niccoli, et al.. (2012). Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET). Pancreas. 41(2). 350–350. 4 indexed citations

20.

Elliott, Dominic, Denis Smith, & Martina C. McGuinness. (2000). Exploring the Failure to Learn: Crises and the Barriers to Learning. 21(3). 17. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact